NCT05374512: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
- State
- Under way
- Phase
- Phase 3
- People
- 644 taking part
- Started
- 16 May 2022
- Primary completion
- 25 Aug 2025
- Arms
- Dato-DXd
- Results
- None posted
- 16 May 2022: Trial registered
- 16 May 2022: Trial started